Clever Culture Systems (ASX: CC5) is an Australian-listed company in the Technology sector with a market capitalisation of $47.9M and the 1033rd-largest security on the ASX by market capitalisation. The CC5 share price is $0.022, down 4.35% today and up 46.67% over the past 12 months. Shares have traded between $0.015 and $0.037 over the past 52 weeks. CC5 trades on a price-to-earnings ratio of 12.29, below the Technology sector median of 13.75. In its most recent reported period (ending 30 June 2025), Clever Culture Systems reported revenue of $5.5M and a net profit of $1.7M (30.8% margin).
About Clever Culture Systems Limited
Based in Adelaide, Australia, Clever Culture Systems Limited, established in 2004, focuses on the innovation, development, and market launch of advanced technological solutions for the medical industry. The company operates internationally, serving markets in Australia, the United States, Sweden, the United Kingdom, China, the Netherlands, and Germany. Its core offering is the Automated Plate Assessment System (APAS), which efficiently images, analyzes, and interprets microbiology culture plates, primarily assisting microbiology laboratories and the pharmaceutical manufacturing sector. The company's portfolio also includes Digital Microbiology and specialized APAS modules—artificial intelligence algorithms designed to enable digital reading of culture plates when integrated with the APAS Independence system. Additionally, Clever Culture Systems is advancing its APAS intelligent imaging technology for diverse applications, including urine screening, infection control testing, and assessing antimicrobial susceptibility. Formerly known as LBT Innovations Limited, the company adopted its current name in November 2024.
